Excessive cost of Lucentis

Australian Journal of Pharmacy

Volumn 91, Issue 1087, 2010, Pages 8-

  O'Shea, John G ^a  

^a Newcastle Technology Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VERTEPORFIN;

AUSTRALIA; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HUMAN; LETTER; NEW ZEALAND; RETINA MACULA AGE RELATED DEGENERATION; UNITED STATES;

EID: 79551658127     PISSN: 03118002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. Abeysiri P, Johnston NR, Molteno AC. Price of bevacizumab for intravitreal injection in New Zealand. Clin Experiment Ophthalmol 2010 38(1):84.
2. Fong DS, Custis P, Howes J, Jin-Wen Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 2010;117:298-302.
3. Tufail A, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459.
4. Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Ophthalmologia 2009;223(6):370-5.
5. Subramanian ML, Ness S, Abedi G, et al. Bevacizumab us ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol. 2009 Dec;148(6):875-82.
6. Valmaggia C, Haueter I, Kloos P, et al. The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis. Klin Monbl Augenheilkd 2009 Apr;226(4):294-8.
7. Ueta T, Yanagi Y, Tamaki T, Yamaguchi T. Cerebrovascular accidents with ranibizumab. Ophthalmology 2009;116:362.
8. Papadopoulou DN, Mendrinos E, Mangioris G, et al. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration Ophthalmology 2009 Sep;116(9):1755-61.
9. Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. Br J Ophthalmol 2004;88:212-7. (Pubitemid 38142089)
10. Lucentis Summary Document, March 2007 PBAC Meeting. Available from www. health.gov.au/internet/main/publishing.nst/Co ntent/ 8273CE4F07D2021FCA2572F800047B3 B/$File/Ranibizumab.pdf.
11. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007 Sep;91(9):1244-6. (Pubitemid 47344908)
12. Chen CY, Wong TV, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol. 2007 Mar;143(3):510-2.
13. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009 Sep;29(3):1067-73.
14. Subramanian ML, Abedi G, Mess S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 2010 Oct 1. [Epub ahead of print].